Obermatt
See Similar Stocks →

Knight Therapeutics

TOR:GUD · CA4990531069
PharmaceuticalsSmall

360

93
EV / EBIT52
Price / Owner Earnings16
Owner Earnings Yield65
Dividend Yield1
Price/Sales93
EV / Gross Profit40
Price/Book67
Return on Capital49
Cash Return on Capital67
Return on Equity45
EBIT Margin39
Gross Profitability41
Cash Conversion97
Accruals57
Owner Earnings Margin73
Sales growth69
Profit Growth70
Owner Earnings Growth62
Reinvestment96
Price momentum57
Debt load53
Refinancing98
Debt Payback100
Liquidity66
Analyst ratings55
Opinion Changes96
Price Target Upside9
Market mood67
Value Creation14/20strong value creator
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Knight Therapeutics generates returns well above its cost of capital, the foundation of durable shareholder value.

Profile

CountryCanada
IndustryPharmaceuticals
SizeSmall
TypePublic Company
ExchangeTSX
Founded2013
Employees413
Websiteknighttx.com
ISINCA4990531069
Last UpdateApr 2, 2026
Index & Theme
Chronic DiseasesHematologyNeurologyCardiovascularPain ManagementPsychiatryCentral Nervous SystemOncologyBiotechnologyMedicalPharmaceutical

Description

Knight Therapeutics Inc. develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices. Business Segments The company operates Innovative Drugs, Branded Generi…

Analysis

Middle-of-the-road

Knight Therapeutics Inc. sits in the middle of our grid: average quality, average price, no obvious signal in either direction.

On valuation, the picture is fair. The owner-earnings multiple stands at 15.9×; owner earnings: the cash an owner could take out each year.

Growth is solid; the safety picture is adequate. The company scores 14/20 on our value-creation score: strong value creator. Analysts lean positive.

No flags apply to this company at this time: accounts, balance sheet, and cash quality all pass. A clean bill of health is meaningful, not just the absence of a warning. This analysis describes numbers; it is not investment advice.

360° rank · history

1007550250
100
2023202420252026

All-time high

100

Jun 2026

All-time low

40

Jan 2023

Average rank

74

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
93
59
60
64
Price/Earnings
1
7
5
4
Price/Book
67
80
79
85
Dividend Yield
1
1
1
1
Value (overall)
47
41
39
45

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Knight Therapeutics with its peers
TherapeuticsMD
NSQ:TXMD
34
CountryUSA
IndustryPharmaceuticals
SizeX-Small
Full Stock Analysis →
Verrica Pharmaceuticals
NAQ:VRCA
55
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Eton Pharmaceuticals
NMQ:ETON
70
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Harmony Biosciences Holdings
NMQ:HRMY
94
CountryUSA
IndustryPharmaceuticals
SizeMedium
Full Stock Analysis →
Innoviva
NSQ:INVA
95
CountryUSA
IndustryPharmaceuticals
SizeMedium
Full Stock Analysis →
Cardiol Therapeutics
TOR:CRDL
81
CountryCanada
IndustryPharmaceuticals
SizeX-Small
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →